Talmapimod (SCIO469) is a potent, selective p38α MAPK inhibitor with IC50 of 9 nM.
Talmapimod (SCIO469) displays 10-fold selectivity for p38α over p38β, >2,000-fold selectivity over a panel of 20 other kinases, including other MAP kinases.
Talmapimod (SCIO469) decreases apoptosis in MDS CD34+ progenitors and leads to dose-dependant increases in erythroid and myeloid colony formation.
Talmapimod (SCIO469) enhances the ability of MG132 and bortezomib to induce the apoptosis of MM cells, and inhibits tumor growth in vivo.
